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Abstract 
Purpose: To report the effect of long-term therapy with the alkylating agent 
cyclophosphamide in a case with serpiginous choroiditis and thus to contribute to the 
previously reported few cases showing the beneficial effect of long-term 
cyclophosphamide therapy for serpiginous choroiditis.  
Procedures: Oral cyclophosphamide therapy for 12 months in a case with unilateral 
active serpiginous choroiditis.  
Results: The active lesion responded well to long-term therapy with cyclophosphamide 
without recurrences and significant systemic side-effects.  
Conclusions: Long-term therapy with cyclophosphamide for serpiginous choroiditis is 
effective for improving vision and preventing recurrences. 
 
Introduction 
Serpiginous choroiditis is considered a bilateral inflammatory disorder of the retinal 
pigment epithelium (RPE) and the choroid [1]. It is reported to start with irregular gray-
white patches representing subretinal infiltration, which show a propensity to 
development near the optic disc or in the posterior pole [1]. A combination of 
immunosuppressives with oral prednisone is recommended to salvage vision in 
serpiginous choroiditis [2]. We report a case with serpiginous choroiditis treated 
successfully with long-term oral cyclophosphamide therapy. 
Case Report 
A 58-year-old white male presented with sudden onset of blurred vision in his left eye (OS). The 
best-corrected visual acuity of the right eye (OD) was 20/400, and OS 20/40 with normal anterior 
segments. The right fundus showed disciform macular and peripapillary chorioretinal scars (fig. 1). The  
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left fundus disclosed a paramacular subretinal infiltrate with creamy yellow, fluffy margins and 
peripapillary chorioretinal scars (fig. 2). Vitreous was clear in both eyes.  
Fluorescein angiogram (FA) OD revealed blockage of the fluoresence corresponding to the areas of 
RPE hypertrophy with staining along the edges (fig. 3). FA OS disclosed early blockage of fluorescein 
followed by leakage and staining corresponding to the paramacular area (fig. 4a, b). The patient’s past 
medical history was significant for a short course of treatment with oral prednisone because of sudden 
onset of blurred vision OD 9 months ago. Tuberculosis, syphilis and toxoplasmosis were considered in 
the differential diagnosis. Blood tests for uveitis work-up, computerized tomography of the chest, and 
tuberculin skin test were negative. The diagnosis of serpiginous choroiditis was considered due to 
bilateral involvement of the peripapillary area and the posterior pole, absence of vitreous cells and 
negative laboratory work-up. Treatment with oral cyclophosphamide 2 mg/kg/day and prednisone 1 
mg/kg/day were initiated. Prednisone dose was tapered gradually and discontinued. Fundus 
examination OS at the 3rd month of cyclophosphamide therapy showed increased pigmentation with 
descrete borders of the previously active paramacular infiltrate (fig. 5). FA OS revealed mottled 
hyperfluorescence due to pigment clumping in the early and late frames (fig. 6a, b). The patient 
received cyclophosphamide for 12 months with no recurrence in either eye, and improving of vision OS 
to 20/20. Best-corrected visual acuity OD remained 20/400. 
Cyclophosphamide was discontinued after 12 months due to microscopic hematuria. The patient is 
currently being followed up. He has been on no medication for 6 months without recurrence in either 
eye. 
Discussion 
The diagnosis and management of serpiginous choroiditis is considered to present a 
challenge [3, 4]. Ocular involvement in serpiginous choroiditis is described as usually 
bilateral, rarely multifocal, and primarily involving the posterior pole, especially around 
the optic disc and extending contiguosly to the macula [3]. No patient with serpiginous 
choroiditis is reported to present with vitritis [3]. However, tuberculous, serpiginous-like 
choroiditis is reported to show significant vitritis and often presents with multifocal 
lesions in the posterior pole and periphery [3]. The clinical presentation of our case is 
most likely compatible with serpiginous choroiditis because of the absence of vitreous 
cells, bilateral involvement of the peripapillary area and the posterior pole, negative 
uveitis work-up including blood tests, computerized tomography of the chest, and 
tuberculin skin test. 
A combination of azathioprine, cyclosporin, and prednisone therapy has been reported 
to provide rapid remission in all 5 patients treated [5]. However, the same source also 
reported the recurrence of choroidal inflammation immediately after cessation of the 
immunosuppressive therapy [5]. Long-term immunosuppressive therapy is indicated to 
prolong remission and preserve vision in patients with serpiginous choroiditis [4]. 
Successful treatment with an alkylating agent, either chlorambucil or cyclophosphamide 
has been reported in 9 patients with active, vision-threatening serpiginous choroiditis [4]. 
Our patient had initially been treated with a short course of oral prednisone for blurred 
vision OD. However, the treatment had not been successful and resulted in the formation 
of a disciform macular scar. Cyclophosphamide treatment combined with prednisone was 
considered as the first-line treatment for active serpiginous lesion OS for this case due to 
profound loss of vision OD. Unilateral active choroiditis OS responded well to long-term 
oral cyclophosphamide therapy without formation of either choroidal neovascularization 
or disciform macular scar. The patient received no adjunctive therapy other than a short 
course of oral prednisone. Successful resolution of the active lesion was achieved in 3 
months of cyclophosphamide therapy. However, the treatment was continued because of  
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the proximity of the lesion to the macula, and because of profound loss of vision OD. The 
following side-effects of cyclophosphamide therapy have been reported: hemorrhagic 
cystitis, bone marrow suppression, anemia, sterility and secondary malignancy [6]. Our 
patient experienced microscopic hematuria after 12 months of therapy. Treatment was 
discontinued because of the possibility of urinary bladder carcinoma. Alternative 
treatment with biologic therapy, such as interferon alpha-2a, has been recommended for 
severe cases who were unable to continue therapy with alkylating agents [7]. Interferon 
alpha-2a was considered in case of recurrences for our case. However, the patient had no 
recurrence during 6 months of follow-up. Since there were few reported cases showing 
the efficacy of long-term therapy with cyclophosphamide in serpiginous choroiditis, we 
believe this case will contribute to the understanding of the beneficial effect of long-term 
cyclophosphamide therapy for improving vision and preventing recurrences without 
significant systemic side-effects. 
Disclosure Statement 
The author did not receive grants or funds in support of the study. 
 
 
 
 
 
 
Fig. 1. Color fundus photograph of disciform macular and peripapillary chorioretinal scars in the right 
eye. 
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Fig. 2. Color fundus photograph of paramacular subretinal infiltrate and peripapillary chorioretinal 
scars in the left eye. 
 
 
 
Fig. 3. Fluorescein angiogram of the right eye. Note the blockage of the fluorescence corresponding to 
the areas of RPE hypertrophy with staining along the edges. 
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Fig. 4. a, b Fluorescein angiogram of the left eye. Note the early blockage of fluorescein followed by 
leakage and staining corresponding to the paramacular area. 
 
 
 
Fig. 5. Color fundus photograph of the left eye at the 3rd month of cyclophosphamide therapy. Note 
the increased pigmentation with discrete borders of the previously active paramacular infiltrate. 
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Fig. 6. a, b Fluorescein angiogram of the left eye at the 3rd month of cyclophosphamide therapy. Note 
the mottled hyperfluorescence due to pigment clumping in the early and late frames. 
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